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BACKGROUND: Prostate cancer (PC) is a leading cause of fatal cancer in men in developed countries. Coeliac disease (CD) has
previously been linked to a raised cancer risk, and changes in some exposures following a CD diagnosis might hypothetically raise
PC risk.
METHODS: We identified 10995 patients with CD who had undergone a small intestinal biopsy in 1969–2007. Statistics Sweden then
identified 54233 age-matched male reference individuals from the general population. PC data were obtained from the Swedish
Cancer Register. Hazard ratios (HRs) for PC were estimated using Cox regression analysis.
RESULTS: During follow-up, 185 individuals with CD (expected n¼200) had an incident diagnosis of PC. This corresponds to a HR of
0.92 (0.79–1.08) (with 95% confidence interval) and an absolute risk reduction of 15/100000 person-years among those with CD.
An increased risk was not observed even when identification of PC began 5 years after biopsy.
CONCLUSION: Our conclusion is that a CD diagnosis does not represent an increased risk for PC.
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Prostate cancer (PC) is one of the leading causes of cancer
mortality in men in industrialised countries (Ferlay et al, 2010).
Established risk-factors for PC include increasing age, ethnic
origin, and hereditary/familial factors. Although the great varia-
bility in incidence across different parts of the world can be
attributed largely to differences in diagnostic intensity, the over
10-fold variation in mortality rates between low-risk countries in
Asia and high-risk countries, such as Sweden (Ferlay et al, 2010),
suggests that environmental factors, such as diet, may account for
some of the observed variation (Shimizu et al, 1991; Hsing and
Devesa, 2001).
Coeliac disease (CD) is an immune-mediated disease that occurs
in 1% of the Western population (Dube et al, 2005). It is
characterised by small intestinal inflammation and villous atrophy
(VA) (Ludvigsson and Green, 2011). The only available treatment
consists of a gluten-free diet where the individual avoids wheat,
barley, and rye (Kupper, 2005), whereas consumption of oats is
safe for patients with CD (Janatuinen et al, 1995).
Earlier research has shown a relative risk for PC in CD of
around 1, with two studies suggesting a lower risk of PC (England:
standardised incidence ratio¼0.67; 95% confidence interval (CI)¼
0.18–1.73) (Goldacre et al, 2008) (Sweden: 0.7; 95% CI¼0.4–1.2)
(Askling et al, 2002), and one study suggesting a positive associa-
tion between positive endomysial antibodies (‘gluten sensitivity’)
and PC (Northern Ireland: 1.78; 95% CI¼0.00–4.24) (Anderson
et al, 2007). All of these studies were, however, based on o20 cases
of PC. Additionally, there are single case-reports of PC in CD
(Green et al, 2003; Card et al, 2004), but with no relative risks
reported.
An association between CD and PC could potentially be
mediated by several factors including dietary changes following
diagnosis, as patients with CD are prescribed a gluten-free diet,
which includes low intake of rye, wheat, barley, and refined grain.
Dietary change could potentially influence PC risk, although the
link between intake of whole grains and PC is unclear. Two small
intervention studies among PC patients have reported associations
between increased rye intake and tumour growth in terms of
reduced PSA-levels and increased apoptosis (Bylund et al, 2003;
Landberg et al, 2010), while observational studies of whole grain
consumption and PC risk show inconsistent results (Chatenoud
et al, 1998; Lewis et al, 2009; Egeberg et al, 2011).
In this study, we tested the hypothesis that men with a diagnosis
of CD have a higher risk of PC. This was tested using longitudinal
Swedish register data for 10995 men with CD and 54233 age-matched
m e ni nt h ec o m p a r i s o nc o h o r t .
MATERIALS AND METHODS
We used national Swedish data from biopsy reports to identify
patients with CD. These data were linked to the Swedish Cancer
Register in order to examine the risk of PC.
Received 6 September 2011; revised 31 October 2011; accepted 9
November 2011; published online 1 December 2011
*Correspondence: Dr JF Ludvigsson; E-mail: jonasludvigsson@yahoo.com
British Journal of Cancer (2012) 106, 217–221
& 2012 Cancer Research UK All rights reserved 0007– 0920/12
www.bjcancer.com
E
p
i
d
e
m
i
o
l
o
g
yPC
PC was defined according to the International Classification of
Disease (ICD) 7-code 177 in the Swedish Cancer Register (equivalent
to ICD-8 and 9: 185 and ICD-10: C61).
CD
From October 2006 to February 2008, data from small intestinal
biopsy reports were collected from each of Sweden’s 28 pathology
departments. The biopsies were performed between 1969 and 2008.
CD was defined as having a biopsy report with VA (equivalent to
Marsh grade 3; see Supplementary Appendix) (Marsh, 1992). We
did not require positive serology for a CD diagnosis, but an earlier
validation study found that among patients with available CD
serology data at the time of biopsy, 88% had positive serology
(Ludvigsson et al, 2009a). The validation study also found that
95% of patients with VA had CD according to medial records
(n¼108/114) and that 79% of patients had gastrointestinal
symptoms at the time of biopsy.
Local IT personnel conducted the searches for relevant biopsy
reports and data on the arrival dates of the biopsies, personal
identity number (Ludvigsson et al, 2009c), morphology according
to the Swedish SnoMed classification codes (for a translation into
international classification systems, see Supplementary Appendix),
and topography (duodenum/jejunum). These data were then
delivered to the researchers. The CD cohort used here was based
on the 29096 individuals with CD and was examined for overall
mortality in a recent paper by our group (Ludvigsson et al, 2009b).
The number of age- and sex-matched controls (identified by the
government agency statistics) individually matched with patients
with CD in that study was 144522.
The CD study sample was then restricted to 11091 male
CD patients (18005 females excluded) (Ludvigsson et al, 2009b).
We then excluded individuals with CD who had a biopsy after
31 December 2007 (n¼5) because our follow-up ended on
31 December 2007 (cancer data available until this date),
individuals with a diagnosis of PC before CD diagnosis (n¼90).
Finally, there was left one individual with CD whose matched
comparators had been excluded for any of the above reasons.
Of the initial 144522 controls, 55300 were males (89222 females
were excluded). We also excluded controls that entered the study
after 31 December 2007 (n¼25), those with a diagnosis of PC
before CD diagnosis (n¼480), and controls whose matched index
individuals with CD had been excluded at some stage (n¼562).
The final sample consisted of 10995 men with CD and 54233 in
the age-matched male comparison cohort.
Statistics
Cox regression was used to estimate relative risks. In our statistical
model, we used internal stratification for age at the time of the first
biopsy (and corresponding age in reference individuals), calendar
period, and county. Our analysis therefore took into account the
influence of age, calendar period, and county (similar to the effect
of use of risk-sets in conditional logistic regression). Follow-up
time started on the date of the first biopsy with VA and on the
corresponding date in matched reference individuals. It ended
with a diagnosis of PC, death, emigration, or on 31 December 2007,
whichever came first. In reference individuals, follow-up could also
end if the individual underwent a small intestinal biopsy. We used
log-minus-log curves to test the proportional hazards assumption
(Figure in Supplementary Appendix showing that this condition
was fulfilled). We also evaluated the risk of PC stratified by follow-
up time (o1 year, 1 to o5 years, and X5 years), sex, age at CD
diagnosis (0–19, 20–39, 40–59, and X60 years at first biopsy),
and calendar period of the first biopsy ( 1989, 1990–1999, and
2000 until present). Death due to PC (based on underlying cause of
death according to death certificates) was used as an alternative
outcome in a subanalysis in an attempt to identify a more
aggressive PC phenotype. Incidence rates were calculated using the
number of first PC events divided by the number of person-years
at risk. The expected number of cases was derived from the
observed number of cases divided by the hazard ratio (HR). In this
way, the expected number of cases is based on the age and sex
distribution of the CD cohort.
We identified individuals with type 1 diabetes using the Swedish
Hospital Discharge Register (see Supplementary Appendix for ICD
codes) (Ludvigsson et al, 2011). Type 1 diabetes is associated with
CD (Bao et al, 1999; Smyth et al, 2008), but inversely associated
with PC, so concomitant type 1 diabetes could therefore potentially
hide a positive association between CD and PC. A subanalysis
excluded all individuals with a diagnosis of type 1 diabetes, irres-
pective of when the diagnosis was made.
In another subanalysis, we adjusted for education using seven
a priori educational categories determined by Statistics Sweden
(o9 years, 9–10 years, p2 years of high school, X3 years of high
school, o3 years of college/university, X3 years of college, and
postgraduate studies). In a third subanalysis, we adjusted for
country of birth (Nordic and non-Nordic countries).
Statistical significance defined as 95% CI for risk estimates not
including 1.0. SPSS 18.0 software (SPSS Inc., Chicago, IL, USA) was
used for the statistical analysis.
RESULTS
Background data
The majority of the participants with CD had a biopsy from 1990
onwards and entered the study at this time, as did the matched
comparison cohort. The median age at diagnosis of PC was 71
years in men with CD and 72 years in the comparison cohort.
Other characteristics of the study participants are listed in Table 1.
Some 3.8% of the individuals with CD but only 0.4% of the
matched controls had a diagnosis of type 1 diabetes before the end
of follow-up (Po0.001, w
2-test).
CD and subsequent PC
During follow-up, there were 185 diagnoses of PC (expected
n¼200), corresponding to a HR of 0.92 (95% CI¼0.79–1.08)
(Table 2). The risk estimate did not change notably when
we excluded individuals with a diagnosis of type 1 diabetes
(0.93; 0.79–1.09). Nor did it change notably when we adjusted for
country of birth (0.92; 0.78–1.07) or education (0.93; 0.78–1.12).
When we excluded the first year of follow-up to minimise
the risk of surveillance bias, the HR was little changed (0.89;
0.75–1.06). After 5 years of follow-up, giving sufficient time for an
influence of the diet, the HR for PC in CD was 1.00 (Table 2).
The differences in PC risk by age at CD diagnosis were not
statistically significant (P-value for interaction: 0.197) (Table 3).
There were no notable differences in risk estimates for PC by
calendar period (P-value for interaction: 0.926).
When death due to PC, indicating more aggressive disease, was
used as an alternative outcome (with 21 deaths among CD patients
and an expected of 36), the HR for the association of CD with PC-
related death remained below 1.00 (data not shown).
DISCUSSION
This study found no association between CD and PC using
longitudinal data. It is one of the first large-scale studies of this
subject and it used histology from intestinal biopsies to identify
CD reliably. Our findings are consistent with the two general
population-based studies from England (Goldacre et al, 2008) and
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more statistical power to detect an association.
Although earlier studies on CD and PC have been based on as
few as 2–14 positive events (Askling et al, 2002; Anderson et al,
2007; Goldacre et al, 2008), we observed 185 PC diagnoses in
patients with CD during follow-up. The greater statistical power of
our study allowed for stratification and greater precision.
CD patients in our cohort were ascertained through biopsy
reports, so they are more likely to have typical CD characteristics
than those identified through inpatient registers as this may signal
comorbidity (Askling et al, 2002; Goldacre et al, 2008), because CD
investigation does not require hospital care. Most adult gastro-
enterologists (96%) and all paediatricians obtain biopsies from the
majority of patients with suspected CD (over 90%) to make the
diagnosis. Therefore, diagnosis of CD among our study population
is highly reliable. Small intestinal biopsies with VA have high
specificity for CD. When two independent researchers examined
more than 1500 biopsy reports with VA or inflammation, o0.3%
of patients suffered from inflammatory bowel disease, which was
the most common comorbidity (other than CD) (Ludvigsson et al,
2009a). Patients with CD are at increased risk of comorbid type 1
diabetes. We performed an analysis where all the individuals with a
diagnosis of type 1 diabetes before the end of follow-up were
excluded. This exclusion did not affect the risk estimates for PC.
One weakness of this study is the lack of individual data on
dietary components or compliance to a gluten-free diet. Some
aspects of dietary compliance could theoretically raise the risk of
PC, although mucosal healing and less chronic inflammation might
reduce the risk. In a validation study of 121 randomly selected
individuals with VA, there were indications of low dietary
compliance in 15/86 individuals (17, 95% CI¼9–25%), thus with
dietary compliance in 83% (Ludvigsson et al, 2009a). This study
found no association between CD and PC (HR¼0.92).
As PC may have a prolonged natural history (Schmid et al,
1993), we also examined risk of PC according to time since
diagnosis of CD. Although there was no association between
CD and PC in the first year beyond biopsy, or more than 5 years
after biopsy, there was a statistically significant reduced risk
of PC 1–5 years after CD diagnosis. We cannot rule out that
there is a true decreased risk of PC in CD due to factors, such as
lower body mass index (BMI) in patients with CD (Discacciati
et al, 2011). In the first year after diagnosis, this may be masked
by an increased ascertainment rate of PC as comorbid conditions
are more likely to be detected during diagnosis or treatment.
With time, the lower PC risk may not persist as mucosal healing
results in increased BMI. It should be noted that the apparent
reduced risk 1–5 years after CD diagnosis could represent a
chance finding.
Although the total follow-up time for patients with CD in this
study was 101000 person-years, we did not have enough follow-up
to estimate the risk of PC in CD diagnosed in childhood. It has
been suggested that an early diagnosis of CD in childhood may
protect against certain cancers (Elfstrom et al, 2011), but as
participants in this study tended to receive a later diagnosis, this
putative protection against cancer could not have concealed a
positive association. Other immune-mediated diseases, such as
type 1 diabetes (Kasper et al, 2009; Shu et al, 2010), ulcerative
colitis (Goldacre et al, 2008), Crohn’s disease (Goldacre et al,
2008), and Wegener’s granulomatosis have been inversely
associated with PC (Knight et al, 2002). This study found no
association between CD and PC.
Also, adolescence represents a critical window of prostate
development, where diet (Andersson et al, 1995) and hormonal
exposure (Barba et al, 2008) could be important. Although we
could investigate participants with a CD diagnosis at younger ages,
it is important to emphasise that there was no evidence of
increased PC risk among men diagnosed with CD from age 40
years: this study would have been able to detect such a risk. This
indicates that middle-aged men who receive a diagnosis of CD
need not be concerned that the diagnosis, or dietary changes
typically associated with it, could increase their risk of PC.
Another potential weakness is our lack of data on BMI. High
BMI has been inversely associated with CD (Olen et al, 2009), but
positively associated with PC (Moller et al, 1994), although most
prospective studies do not support this association (Rodriguez
et al, 2007; Wright et al, 2007). Neither did we have any data on
smoking. Smoking may increase the risk of PC (Plaskon et al, 2003).
Although several studies have indicated an inverse relationship
between smoking and CD (Vazquez et al, 2001; Austin et al, 2002),
Table 2 Risk of prostate cancer by follow-up time
Follow-up
Observed
events
Expected
events HR 95% CI P-value
Absolute
risk/100000 PYAR
Excess
risk/100000 PYAR
Attributable
percentage
All 185 200 0.92 0.79–1.08 0.336 182  15  8
Year o1 22 18 1.23 0.78–1.96 0.374 204 39 19
1–4.99 48 67 0.71 0.53–0.97 0.030 133  54  40
5+ 115 115 1.00 0.82–1.23 0.985 209 0 0
Abbreviations: CI¼confidence interval; HR¼hazard ratio; PYAR¼person-years at risk. Reference is general population comparator cohort. The attributable percentage was
calculated as (1–1/HR).
Table 1 Characteristics of the study participants
Matched
controls
Patients
with CD
Total 54233 10995
Age and follow-up
Age at study entry, years
(median, range)
34; 0–95 35; 0–95
Age 0–19 (%) 21734 (40.1) 4356 (39.6)
Age 20–39 (%) 8216 (15.1) 1659 (15.1)
Age 40–59 (%) 12946 (23.9) 2605 (23.7)
Age X60 (%) 11337 (20.9) 2375 (21.6)
Entry year (median, range) 1998; 1969–2007 1998; 1969–2007
Follow-up, years (median, range)
a 8; 0–39 8; 0–37
Follow-up, years (mean±SD)
a 9.5±6.4 9.3±6.4
Calendar year
-1989 (%) 8101 (14.9) 1643 (14.9)
1990–1999 (%) 22824 (42.1) 4627 (42.1)
2000- (%) 23308 (43.0) 4725 (43.0)
Covariates
Nordic country of birth (%)
b 51241 (94.5) 10662 (97.0)
Type 1 diabetes (%) 208 (0.4) 418 (3.8)
Abbreviation: CD¼coeliac disease.
aFollow-up time until diagnosis of prostate,
death from other cause, emigration, or 31 December 2007. In reference individuals,
follow-up could end if the patients underwent a small intestinal biopsy.
bSweden,
Denmark. Finland, Norway, and Iceland.
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risk for later CD in smokers (adjusted Odds ratio¼1.25; 95% CI¼
0.94–1.67) (Ludvigsson et al, 2005). Although unlikely, we cannot
rule out the possibility that lower BMI and a lack of smoking
among individuals with CD may have hidden a modest association
between CD and PC.
PSA-testing has, since it was introduced during the 90s, resulted
in a rising overdiagnosis of PC (i.e., detection of nonlethal pseudo-
tumours) and it is becoming increasingly important to separate
clinically significant PC from indolent disease in aetiological
studies. The Swedish Cancer Registry covers essentially all incident
PCs, but lacks information on tumour stage and Gleason grade.
Although PSA-screening is less common in Sweden than in the
United States and many other Western countries, around 40% of
the cases were diagnosed with screening-detected PC in Sweden
during the latter part of the study period (National Prostate Cancer
Register, http://www.roc.se/prostata.asp). We tackled this through
a subanalysis that used death due to PC as the outcome to identify
more aggressive disease. Again, there was no raised risk associated
with a CD diagnosis.
In conclusion, patients with CD seem to be at no increased risk
of PC.
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